Browse > Article
http://dx.doi.org/10.15324/kjcls.2021.53.2.137

The Patterns of Acquiring Anti-Mycobacterial Drug Resistance by Susceptible Strains of Mycobacterium tuberculosis  

Lee, Kyutaeg (Department of Laboratory Medicine, Green Cross Laboratories)
Chong, Moo-Sang (Department of Clinical Laboratory Science, Cheju Halla University)
Publication Information
Korean Journal of Clinical Laboratory Science / v.53, no.2, 2021 , pp. 137-142 More about this Journal
Abstract
This study investigated the patterns of acquiring anti-mycobacterial resistance in individuals who were susceptible to all anti-mycobacterial drugs in their initial treatment. From 2010 to 2019, anti-mycobacterial drug susceptibility tests were conducted on patients who were referred to the Green Cross Laboratories. The test results of 594 anti-mycobacterial drug sensitivity tests were collected at 111 medical institutions. The first test results had 594 cases in which all anti-mycobacterial drugs were susceptible. Isoniazid (INH), rifampin (RIF), streptomycin (SM), and quinolone (QUI) showed the highest single-resistant conversion rates. Out of 56 patients, 17 patients (30.4%) showed a high conversion rate of resistance to both INH and RIF. The tracking period was analyzed from a minimum of 98 days to 1,862 days, and an average of 435.6 days for INH, and a minimum of 108 days to 1,673 days, with an average of 457.7 days for RIF. In the case of tuberculosis patients who are susceptible to all anti-mycobacterial drugs, it is considered that the conversion to resistant and multi-drug resistant tuberculosis (MDR-TB) must be confirmed through an anti-mycobacterial susceptibility test after 3 months. It is hoped that this study will help the national tuberculosis management project to improve public health.
Keywords
Anti-mycobacterial; Anti-tuberculosis; Multi-drug resistant tuberculosis; Resistance acquiring patterns;
Citations & Related Records
연도 인용수 순위
  • Reference
1 World Health Organization. Guidelines for treatment of tuberculosis, fourth edition. Geneva, Switzerland; World Health Organization, 2010.
2 Mitchison DA. Drug resistance in tuberculosis. Eur Respir J. 2005;25:376-379. https://doi.org/10.1183/09031936.05.00075704   DOI
3 Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2019. Seoul: Korea Centers for Disease Control and Prevention, 2020 March. p16-59.
4 Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136:420-425. https://doi.org/10.1378/chest.08-2427   DOI
5 Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 2001;344:1294-1303. https://doi.org/10.1056/NEJM200104263441706   DOI
6 World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis: emergency update 2008. Geneva, Switzerland; World Health Organization, 2008.
7 David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:810-814. https://doi.org/10.1128/aem.20.5.810-814.1970   DOI
8 Bloch AB, Cauthen GM, Onorato IM, Dansbury KG, Kelly GD, Driver CR, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994;271:665-671. https://doi.org/10.1001/jama.271.9.665   DOI
9 Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet. 2009;373:1861-1873. https://doi.org/10.1016/S0140-6736(09)60331-7   DOI
10 Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med. 2010;363:1050-1058. https://doi.org/10.1056/NEJMra0908076   DOI
11 Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007;11:571-576.
12 Meacci F, Orru G, Iona E, Giannoni F, Piersimoni C, Pozzi G, et al. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol. 2005;43: 3114-3120. https://doi.org/10.1128/jcm.43.7.3114-3120.2005   DOI
13 Joint Committee for the Development of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 1st ed. Seoul; Korea Centers for Disease Control and Prevention, 2011:34-36.
14 Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med. 2006;174: 935-952. https://doi.org/10.1164/rccm.200510-1666st   DOI
15 von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7:249-259. https://doi.org/10.1016/s2213-2600(18)30426-0   DOI
16 Singh J, Garg PK, Tandon RK. Hepatotoxicity due to anti-tuberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol. 1996;22:211-214. https://doi.org/10.1097/00004836-199604000-00012   DOI
17 Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305. https://doi.org/10.1037/e566482006-002   DOI
18 Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 1998;338:1641-1649. https://doi.org/10.1056/NEJM199806043382301   DOI
19 Oh SH, Kim YJ, Park SK, Hwang SH, Kim HH, Lee EY, et al. Comparison of anti-mycobacterial drug susceptibility test results by institutes and methods. Korean J Clin Microbiol. 2008;11: 43-48. https://doi.org/10.5145/kjcm.2008.11.1.43   DOI
20 Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh YS, et al. Comparison of effectiveness and adverse reactions between isoniazid 300 mg and 400 mg in korean patients with pulmonary tuberculosis. Tuberc Respir Dis. 2006;60:44-48. https://doi.org/10.4046/trd.2006.60.1.44   DOI
21 Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13:1320-1330.
22 Joint Committee for the Development of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 4th ed. Seoul; Korea Centers for Disease Control and Prevention, 2020 May. p13-15.
23 Kim JY, Park YJ, Lee NY, Chang CL, Lee MA, Shin JH. Anti-tuberculosis drug resistant rates in Mycobacterium tuberculosis isolated from respiratory specimens: A multicenter study in Korea. Ann Clin Microbiol. 2013;16:1-7. https://doi.org/10.5145/acm.2013.16.1.1   DOI
24 Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380:1201-1213. https://doi.org/10.1056/NEJMoa1811867   DOI
25 Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5:291-360. https://doi.org/10.1016/S2213-2600(17)30079-6   DOI
26 Chang KC, Nuermberger E, Sotgiu G, Leung CC. New drugs and regimens for tuberculosis. Respirology. 2018;23:978-990. https://doi.org/10.1111/resp.13345   DOI
27 Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167: 603-662. https://doi.org/10.1164/rccm.167.4.603   DOI